Graph with closing prices (blue curve) and volumes (red bars)

The graph has been adjusted for splits, reverse splits, issues and dividends
Graph for Senzime
Choose Date Horizon > 3 years 3 years 1 year 3 months 1 month 1 week Today
Fler nyheter från Finwire

Nyheter från nyhetsbyrån Finwire (upp till 15 min fördröjning)

8/21/20143:06 PMFinwire om Senzime: Senzime ökade omsättningen i första halvåret
6/4/20144:07 PMFinwire om Senzime: Senzime ser väldigt positivt på att nå ut i öppenvården och inte bara sjukhus - vd
6/3/201410:06 AMFinwire om Senzime: Senzime inleder samarbete med ProHelia

Company Information

Company NameSenzime AB
Company Idea

Senzime develops and sells analytical instruments and related disposable products that enable automated, continuous monitoring of vital substances including glucose (sugar), in biological fluids. Many modern medicines are produced in living cells that are nourished in a glucose solution. In order to ensure maximum productivity in manufacturing, glucose levels should be measured continuously. BioSenz is an analytical instrument that performs this task. Senzime's market leading partner, Applikon, has started the global launch of BioSenz. Continuous glucose monitoring can also be used by healthcare providers, to improve outcomes of complex surgical procedures and dialysis care. For these purposes, the company develops the instrument CliniSenz. The company's share is listed on Aktietorget since 2008.

Phone018-51 56 40CEOLena Söderström
E-mailinfo(snabel-a)senzime(punkt)comChairm. of the BoardAdam Dahlberg

Instrument Information

Full NameSenzimeShort NameSEZI
No of shares11,022,246Par Value2.5 SEK
TypeShareISIN codeSE0002478776

Price Information

Turnover (SEK)700
Market Cap (MSEK)77.2




9:53 AMSHBCAD7.00100

Scheduled Reports

2014-11-27Delårsrapport tre

  • Mäster Samuelsgatan 42
  • 111 57 Stockholm
  • Telefon: 08 - 511 68 000
  • info(snabel-a)aktietorget(punkt)se